These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 28081149)

  • 1. Rationale for Further Development of a Vaccine Based on the Circumsporozoite Protein of Plasmodium vivax.
    Yadava A; Waters NC
    PLoS Negl Trop Dis; 2017 Jan; 11(1):e0005164. PubMed ID: 28081149
    [No Abstract]   [Full Text] [Related]  

  • 2. Tailoring a Plasmodium vivax Vaccine To Enhance Efficacy through a Combination of a CSP Virus-Like Particle and TRAP Viral Vectors.
    Atcheson E; Bauza K; Salman AM; Alves E; Blight J; Viveros-Sandoval ME; Janse CJ; Khan SM; Hill AVS; Reyes-Sandoval A
    Infect Immun; 2018 Sep; 86(9):. PubMed ID: 29986894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances toward the development of an asexual blood stage MSP-1 vaccine of Plasmodium vivax.
    Levitus G; del Portillo HA
    Mem Inst Oswaldo Cruz; 1994; 89 Suppl 2():81-4. PubMed ID: 7565138
    [No Abstract]   [Full Text] [Related]  

  • 4. Towards a vaccine against Plasmodium vivax malaria.
    Beeson JG; Crabb BS
    PLoS Med; 2007 Dec; 4(12):e350. PubMed ID: 18092888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy.
    Bennett JW; Yadava A; Tosh D; Sattabongkot J; Komisar J; Ware LA; McCarthy WF; Cowden JJ; Regules J; Spring MD; Paolino K; Hartzell JD; Cummings JF; Richie TL; Lumsden J; Kamau E; Murphy J; Lee C; Parekh F; Birkett A; Cohen J; Ballou WR; Polhemus ME; Vanloubbeeck YF; Vekemans J; Ockenhouse CF
    PLoS Negl Trop Dis; 2016 Feb; 10(2):e0004423. PubMed ID: 26919472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological, immunological and functional properties of two novel multi-variant chimeric recombinant proteins of CSP antigens for vaccine development against Plasmodium vivax infection.
    Shabani SH; Zakeri S; Salmanian AH; Amani J; Mehrizi AA; Snounou G; Nosten F; Andolina C; Mourtazavi Y; Djadid ND
    Mol Immunol; 2017 Oct; 90():158-171. PubMed ID: 28800475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of a prime-boost vaccine containing the circumsporozoite proteins of Plasmodium vivax in rodents.
    Teixeira LH; Tararam CA; Lasaro MO; Camacho AG; Ersching J; Leal MT; Herrera S; Bruna-Romero O; Soares IS; Nussenzweig RS; Ertl HC; Nussenzweig V; Rodrigues MM
    Infect Immun; 2014 Feb; 82(2):793-807. PubMed ID: 24478093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prime-boost vaccination with recombinant protein and adenovirus-vector expressing Plasmodium vivax circumsporozoite protein (CSP) partially protects mice against Pb/Pv sporozoite challenge.
    de Camargo TM; de Freitas EO; Gimenez AM; Lima LC; de Almeida Caramico K; Françoso KS; Bruna-Romero O; Andolina C; Nosten F; Rénia L; Ertl HCJ; Nussenzweig RS; Nussenzweig V; Rodrigues MM; Reyes-Sandoval A; Soares IS
    Sci Rep; 2018 Jan; 8(1):1118. PubMed ID: 29348479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel chimeric Plasmodium vivax circumsporozoite protein induces biologically functional antibodies that recognize both VK210 and VK247 sporozoites.
    Yadava A; Sattabongkot J; Washington MA; Ware LA; Majam V; Zheng H; Kumar S; Ockenhouse CF
    Infect Immun; 2007 Mar; 75(3):1177-85. PubMed ID: 17158893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective efficacy of a Plasmodium vivax circumsporozoite protein-based vaccine in Aotus nancymaae is associated with antibodies to the repeat region.
    Yadava A; Hall CE; Sullivan JS; Nace D; Williams T; Collins WE; Ockenhouse CF; Barnwell JW
    PLoS Negl Trop Dis; 2014 Oct; 8(10):e3268. PubMed ID: 25329054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A universal vaccine candidate against Plasmodium vivax malaria confers protective immunity against the three PvCSP alleles.
    Gimenez AM; Salman AM; Marques RF; López-Camacho C; Harrison K; Kim YC; Janse CJ; Soares IS; Reyes-Sandoval A
    Sci Rep; 2021 Sep; 11(1):17928. PubMed ID: 34504134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platform for Plasmodium vivax vaccine discovery and development.
    Valencia SH; Rodríguez DC; Acero DL; Ocampo V; Arévalo-Herrera M
    Mem Inst Oswaldo Cruz; 2011 Aug; 106 Suppl 1(Suppl 1):179-92. PubMed ID: 21881773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Library of Plasmodium vivax Recombinant Merozoite Proteins Reveals New Vaccine Candidates and Protein-Protein Interactions.
    Hostetler JB; Sharma S; Bartholdson SJ; Wright GJ; Fairhurst RM; Rayner JC
    PLoS Negl Trop Dis; 2015 Dec; 9(12):e0004264. PubMed ID: 26701602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An update on the search for a Plasmodium vivax vaccine.
    Herrera S; Corradin G; Arévalo-Herrera M
    Trends Parasitol; 2007 Mar; 23(3):122-8. PubMed ID: 17258937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the safety and immunogenicity in rhesus monkeys of a recombinant malaria vaccine for Plasmodium vivax with a synthetic Toll-like receptor 4 agonist formulated in an emulsion.
    Lumsden JM; Pichyangkul S; Srichairatanakul U; Yongvanitchit K; Limsalakpetch A; Nurmukhambetova S; Klein J; Bertholet S; Vedvick TS; Reed SG; Sattabongkot J; Bennett JW; Polhemus ME; Ockenhouse CF; Howard RF; Yadava A
    Infect Immun; 2011 Sep; 79(9):3492-500. PubMed ID: 21690242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human antibodies against DBP.
    Richards JS; Ramsland PA
    Nat Microbiol; 2019 Sep; 4(9):1428-1429. PubMed ID: 31439930
    [No Abstract]   [Full Text] [Related]  

  • 17. Live attenuated pre-erythrocytic malaria vaccines.
    Keitany GJ; Vignali M; Wang R
    Hum Vaccin Immunother; 2014; 10(10):2903-9. PubMed ID: 25483648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of single versus mixed allele vaccines of Plasmodium vivax Duffy binding protein region II.
    Ntumngia FB; Schloegel J; McHenry AM; Barnes SJ; George MT; Kennedy S; Adams JH
    Vaccine; 2013 Sep; 31(40):4382-8. PubMed ID: 23916294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-mediated and cellular immune responses induced in naive volunteers by vaccination with long synthetic peptides derived from the Plasmodium vivax circumsporozoite protein.
    Arévalo-Herrera M; Soto L; Perlaza BL; Céspedes N; Vera O; Lenis AM; Bonelo A; Corradin G; Herrera S
    Am J Trop Med Hyg; 2011 Feb; 84(2 Suppl):35-42. PubMed ID: 21292876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural basis for inhibition of Plasmodium vivax invasion by a broadly neutralizing vaccine-induced human antibody.
    Rawlinson TA; Barber NM; Mohring F; Cho JS; Kosaisavee V; Gérard SF; Alanine DGW; Labbé GM; Elias SC; Silk SE; Quinkert D; Jin J; Marshall JM; Payne RO; Minassian AM; Russell B; Rénia L; Nosten FH; Moon RW; Higgins MK; Draper SJ
    Nat Microbiol; 2019 Sep; 4(9):1497-1507. PubMed ID: 31133755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.